Table 1 Characteristics of the included studies
Author and Year, Tumor type, Registration Number, Stage | Regions | Age(years) | Gender (male,%) | Interventions | Participants | Random and blind method | outcomes | Period of study |
|---|---|---|---|---|---|---|---|---|
Natale R (2009), Non-Small Cell Lung Cancer, NCT00413283, Phase 2 | USA, Europe, Canada, Austria | 63.8 ± 10.8 | 75% | Romiplostim 250 µg | N = 16 | 1:1:1:1Random, double-blind | Chemotherapy dose reduction or delays, grade 3 or 4 thrombocytopenia, platelet transfusion, AEs, serious AEs | 4 months |
62.5 ± 7.7 | 66.7% | Romiplostim 500 µg | N = 18 | |||||
65.4 ± 8.2 | 88.2% | Romiplostim 750 µg | N = 17 | |||||
59.8 ± 6.6 | 50% | Placebo | N = 12 | |||||
Winer(2015), Solid tumors, NCT01147809, Phase 1 | USA, Europe, India | 55.0(34.0–74.0) | 47% | Eltrombopag 100 mg | N = 19 | 3:1Random, double-blind | Chemotherapy dose reduction or delays, grade 3 or 4 thrombocytopenia, platelet count > 400 × 109/L, AEs, serious AEs, thrombosis, mortality | 6 cycles of chemotherapy |
61.0(31.0–81.0) | 43% | Placebo | N = 7 | |||||
Winer(2017), Solid tumors, Not given, Phase 2 | USA, Europe | 67.0(36.0–82.0) | 55.8% | Eltrombopag 100 mg | N = 52 | 2:1Random, double-blind | Bleeding events, platelet transfusion, chemotherapy dose reduction or delays, grade 3 or 4 thrombocytopenia, AEs, serious AEs, thrombosis | 6 cycles of chemotherapy |
66.0(44.0–83.0) | 43.5% | Placebo | N = 23 | |||||
Al-Samkari(2022), Solid tumors, NCT03471078, Phase 3 | USA, Europe、China | 62.0(52.0–69.0) | 48% | Avatrombopag 60 mg | N = 82 | 2:1Random, double-blind | Bleeding events, platelet transfusion, chemotherapy dose reduction or delays, grade 3 or 4 thrombocytopenia, platelet count > 400 × 109/L; AEs, serious AEs, thrombosis, mortality. | Not given |
63.5(54.0–67.0) | 45% | Placebo | N = 40 | |||||
Mantha(2019), Solid tumors, NCT02052882, Phase 2 | USA | 50.0(30.0–76.0) | 30% | Romiplostim | N = 15 | 2:1Random, open | Platelet transfusion, AEs, serious AEs | 3 weeks after enrollment |
67.0(46.0–77.0) | 75% | Observation group | N = 8 | |||||
Kellum(2010), Solid tumors, NCT00102726, Phase 2 | USA, European Union, Asia, South America | 58.5(35.0–75.0) | 52% | Eltrombopag 50 mg | N = 44 | 1:1:1:1Random, double-blind | Bleeding events, platelet count > 400 × 109/L; AEs, thrombosis, mortality | Not given |
59.0 (33.0–75.0) | 36% | Eltrombopag 75 mg | N = 44 | |||||
58.0 (34.0–81.0) | 52% | Eltrombopag 100 mg | N = 46 | |||||
58.0(23.0–73.0) | 35% | Placebo | N = 46 |